Vical, Inc. (NASDAQ:VICL)

CAPS Rating: 4 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Recs

0
Player Avatar pchop123 (79.82) Submitted: 4/8/2013 10:15:54 AM : Underperform Start Price: $4.14 VICL Score: +5.32

not optomistic about its key clinical trial now

Featured Broker Partners


Advertisement